Skip to main content

Table 5 Sensitivity analysis of response rate

From: Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis

Removed study

p

I2 (%)

Odds ratio (95% CI)

0.38

7

2.12 (1.57, 2.85)

Chen Q [15]

0.39

6

2.06 (1.53, 2.78)

Song WC [13]

0.31

14

2.10 (1.54, 2.87)

Wang ZF [14]

0.34

11

2.06 (1.51, 2.80)

Wu F [12]

0.38

7

2.21 (1.62, 3.01)

Wang QZ [23]

0.34

10

2.19 (1.61, 2.98)

Zhang YY [24]

0.30

14

2.13 (1.56, 2.89)

Lv Y [16]

0.30

14

2.11 (1.56, 2.86)

Shi HL [21]

0.38

7

2.12 (1.57, 2.85)

Wang W [19]

0.72

0

1.88 (1.37, 2.58)

Xun Yu [20]

0.38

6

2.06 (1.52, 2.79)

Yang L [22]

0.30

14

2.12 (1.57, 2.88)

Yang L [17]

0.31

14

2.14 (1.56, 2.92)

Zheng X [18]

0.32

13

2.07 (1.51, 2.84)

Hong S [25]

0.73

0

2.50 (1.80, 3.47)